News
In a decision filed March 28, Hon. Steven C. Seeger granted The Lansing Journal’s motion to dismiss the lawsuit filed by Lan-Oak Park District ...
A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...
Merck & Co. Inc. closed 41.19% below its 52-week high of $134.63, which the company reached on June 25th.
NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...
Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...
March 25 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals (600276.SS), opens new tab worth up to $2 billion ...
Leaders at Merck & Co. Inc. are facing a new derivative shareholder lawsuit over allegations that they made misleading ...
4d
News-Medical.Net on MSNAdvancing Adherent Cell Assays with SemaCyte® TechnologySemarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance ...
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results